Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OIG Investigates NuVasive’s Medicare, Medicaid Claims

This article was originally published in The Gray Sheet

Executive Summary

NuVasive revealed June 30 that it was recently subpoenaed by OIG as part of an investigation into potentially false or improper Medicare and Medicaid claims. The company’s stock price fell more than 12 percent July 31, the day after its second quarter earnings report.

You may also be interested in...



NuVasive Settles With DOJ On Medicare Fraud Charges

The spine device firm announced a definitive settlement with the Department of Justice, with a fine of $13.5 million, plus fees and accrued interest

PODs Alert: HHS Inspector General Issues Fraud Warning For Physician-Owned Device Distributors

The March 26 special fraud alert reiterates the HHS watchdog’s “longstanding position that the opportunity for a referring physician to earn a profit, including through an investment in an entity for which he or she generates business, could constitute illegal remuneration under the anti-kickback statute.”

Ortho Industry Reaches $311 Mil. Settlement With DoJ On Kickback Charges

Four major hip and knee implant manufacturers will pay the government a total of $311 million to settle anti-kickback claims resulting from a two-year Department of Justice and HHS investigation into the companies' financial relationships with surgeons, the New Jersey U.S. Attorney's office announced Sept. 27

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT032301

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel